{
    "clinical_study": {
        "@rank": "126205", 
        "arm_group": {
            "arm_group_label": "CBD", 
            "arm_group_type": "Experimental", 
            "description": "Open label CBD"
        }, 
        "brief_summary": {
            "textblock": "Single subject repeated measures design of an open label administration of Cannabidiol (CBD)\n      to 5 participants withdrawing from cannabis use in an inpatient setting. 300mg of CBD will\n      be administered once on day 1, twice on days 2-5 and once on day 6. Participants will be\n      discharged on day 7. CBD will be administered orally in capsules."
        }, 
        "brief_title": "Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cannabis Use Disorder", 
        "condition_browse": {
            "mesh_term": "Marijuana Abuse"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Participants must be seeking treatment for cannabis use disorder and\n        report having experienced cannabis withdrawal symptoms in past quit attempts (as defined\n        by participants' experiencing 3 or more symptoms after cessation of prolonged cannabis use\n        or continuing use to avoid withdrawal symptoms).  They must meet the criteria for a DSMV\n        current cannabis use disorder and test positive to THC on urinary dip stick test on\n        admission. They must be aged 18-65 and speak English.\n\n        Exclusion Criteria: The aim is to exclude individuals with concurrent conditions that\n        jeopardise patient safety or confound study data interpretation.  These include (a)\n        presence of another substance use disorder, operationalized as (i) more than twice weekly\n        use of an illicit drug in the last 90 days (other than cannabis), (ii) alcohol AUDIT\n        scores of greater than 15, or a current history of alcohol dependence, (iii) substance use\n        treatment in the last 30 days, or (iv) current prescription drug abuse or dependence\n        (benzodiazepines, opioids or psychostimulants); (b) evidence of unstable or severe medical\n        conditions or cognitive or psychiatric impairment (including developmental disorder,\n        schizophrenia or other psychotic disorders) that may prevent participation; (f) known or\n        suspected allergy to propylene glycol, corn oil; (h) women of child bearing age not on a\n        reliable contraceptive or men intending to start a family with one month of trial\n        participation; (i) pregnant or lactating women; (j) not available for follow-up; (k) no\n        access to telephone; or (l) unwillingness to provide written confirmation that they have\n        been informed about, and will comply with, exclusion from driving when receiving\n        medication.  Only persons meeting all criteria will be assessed by trial medical officers\n        and research staff as appropriate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083874", 
            "org_study_id": "NCPIC2014001"
        }, 
        "intervention": {
            "arm_group_label": "CBD", 
            "intervention_name": "CBD", 
            "intervention_type": "Drug", 
            "other_name": "No brand names as cannabidiol is not commercially available"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cannabidiol", 
            "CBD", 
            "marijuana", 
            "withdrawal", 
            "treatment"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "number_of_arms": "1", 
        "official_title": "Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study", 
        "overall_official": {
            "affiliation": "Nepean Blue Mountains Local Health District", 
            "last_name": "Martin Weltman, PhD MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Reduction of number and severity of withdrawal symptoms including insomnia, anxiety, agitation, restlessness, low mood. This will be assessed using the only validated scale: The Cannabis Withdrawal Scale", 
                "measure": "Severity of cannabis withdrawal", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Unwanted effects of any nature will be monitored using the reporting protocols employed in similar studies and monitored by senior addiction specialists. Any SAEs will be reported to the TGA as required.", 
                "measure": "Safety of CBD for cannabis withdrawal", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083874"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of New South Wales", 
            "investigator_full_name": "Jan Copeland", 
            "investigator_title": "Professor/Director NCPIC", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Retention in inpatient treatment will be assessed against previous studies of cannabis treatment retention and TAU participants in the unit", 
            "measure": "Treatment retention", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "source": "The University of New South Wales", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of New South Wales", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}